Pfizer Inc. $PFE Shares Sold by TD Private Client Wealth LLC

TD Private Client Wealth LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 21.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 184,275 shares of the biopharmaceutical company’s stock after selling 49,405 shares during the quarter. TD Private Client Wealth LLC’s holdings in Pfizer were worth $4,588,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in PFE. Franklin Resources Inc. grew its stake in shares of Pfizer by 47.8% during the 3rd quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock worth $638,787,000 after purchasing an additional 8,108,887 shares during the period. Vanguard Group Inc. grew its stake in shares of Pfizer by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after purchasing an additional 7,031,162 shares during the period. Neuberger Berman Group LLC grew its stake in Pfizer by 203.8% in the 3rd quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company’s stock valued at $229,346,000 after acquiring an additional 6,045,763 shares during the period. Ameriprise Financial Inc. increased its holdings in Pfizer by 48.2% in the 3rd quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock worth $468,174,000 after acquiring an additional 5,978,927 shares in the last quarter. Finally, AQR Capital Management LLC increased its holdings in Pfizer by 120.9% in the 3rd quarter. AQR Capital Management LLC now owns 9,505,615 shares of the biopharmaceutical company’s stock worth $230,986,000 after acquiring an additional 5,202,884 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the subject of several recent analyst reports. CICC Research initiated coverage on shares of Pfizer in a report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price target for the company. Morgan Stanley boosted their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. Citigroup boosted their price target on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, April 29th. Bank of America cut their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. Finally, Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $28.84.

Pfizer Stock Down 0.1%

Shares of PFE opened at $25.31 on Tuesday. The firm has a market cap of $144.22 billion, a P/E ratio of 19.32 and a beta of 0.35. Pfizer Inc. has a 12-month low of $22.64 and a 12-month high of $28.75. The company’s 50-day moving average price is $26.96 and its 200 day moving average price is $26.20. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. Pfizer’s revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.8%. The ex-dividend date is Friday, May 8th. Pfizer’s payout ratio is 131.30%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.